At a Glance
- Companies: Takeda Pharmaceuticals America, Inc.
- Location: Deerfield, Illinois, USA (HQ); multiple states (layoffs)
- Headline Figure: 243 remote US jobs cut; ~190 neuroscience sales roles
- Focus area: Neuroscience sales force reduction
- Next steps: Reprioritise resources for new launches
What happened?
Takeda Pharmaceuticals is eliminating 243 remote US jobs, with nearly 190 in neuroscience sales roles including sales specialists, reps and district managers across Texas, California, Ohio and Tennessee. The cuts, reported by Boston Business Journal, stem from a “strategic decision” ahead of Trintellix (vortioxetine) patent expiry and generic entry.
Why does it matter?
Trintellix, approved for major depressive disorder, generated ~$500m US sales in FY2025 but faces loss of exclusivity, prompting commercial realignment. Layoffs reflect pharma’s response to patent cliffs, shifting resources from mature assets to pipeline launches amid cost pressures.
Who’s behind it?
Takeda’s US neuroscience team promoted Trintellix and Vyvanse (ADHD), but generics erode revenue. The firm plans new US launches, per spokesperson.
How was it achieved?
WARN notices flagged the remote cuts; spokesperson confirmed neuroscience focus tied to Trintellix transition and portfolio reprioritisation.
What’s next?
Takeda will redirect sales/marketing to growth areas while monitoring generic impact. Broader neuroscience strategy may evolve post‑Trintellix.
What are people saying?
Spokesperson: “Strategic decision to navigate loss of exclusivity for Trintellix while preparing for new medication launches.” BBJ noted cuts affect sales infrastructure as generics loom.